SSH2

Across TCGA pan-cancer cohorts, SSH2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SSH2 data layer compared with 24 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SSH2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SSH2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

PDAC, HNSC, and LUAD are the cancer types where SSH2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.302	0.659	<.001	34	view →
HNSC	OS	Tertile	All	0.907	1.000	.013	8	view →
LUAD	DFS	Median	III,IV	0.958	0.560	.024	4	view →
LSCC	OS	Tertile	All	1.000	0.715	.030	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

SSH2–PDAC (OS)

Open the PDAC breakdown →